Regeneron Pharmaceuticals (REGN) Competitors $701.85 -6.40 (-0.90%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends REGN vs. AMGN, VRTX, GILD, ALNY, BIIB, UTHR, NBIX, INCY, BMRN, and EXASShould you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry. Regeneron Pharmaceuticals vs. Amgen Vertex Pharmaceuticals Gilead Sciences Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings. Do analysts recommend REGN or AMGN? Regeneron Pharmaceuticals presently has a consensus target price of $1,052.90, indicating a potential upside of 50.02%. Amgen has a consensus target price of $319.67, indicating a potential upside of 21.37%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.70Amgen 2 Sell rating(s) 12 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.40 Which has stronger valuation and earnings, REGN or AMGN? Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$13.85B5.57$3.95B$40.4117.37Amgen$32.53B4.35$6.72B$7.8133.72 Do institutionals and insiders believe in REGN or AMGN? 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor REGN or AMGN? In the previous week, Regeneron Pharmaceuticals had 15 more articles in the media than Amgen. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 13 mentions for Amgen. Amgen's average media sentiment score of 0.56 beat Regeneron Pharmaceuticals' score of 0.45 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 8 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Amgen 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, REGN or AMGN? Regeneron Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Is REGN or AMGN more profitable? Regeneron Pharmaceuticals has a net margin of 33.61% compared to Amgen's net margin of 13.00%. Amgen's return on equity of 168.35% beat Regeneron Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals33.61% 16.88% 13.23% Amgen 13.00%168.35%11.18% Does the MarketBeat Community prefer REGN or AMGN? Amgen received 6 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 72.11% of users gave Amgen an outperform vote while only 66.99% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRegeneron PharmaceuticalsOutperform Votes154066.99% Underperform Votes75933.01% AmgenOutperform Votes154672.11% Underperform Votes59827.89% SummaryRegeneron Pharmaceuticals beats Amgen on 10 of the 18 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REGN vs. The Competition Export to ExcelMetricRegeneron PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.13B$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio17.3710.5489.7417.18Price / Sales5.57195.791,116.12116.95Price / Cash16.9057.1642.8237.86Price / Book2.975.094.774.78Net Income$3.95B$151.83M$120.15M$225.60M7 Day Performance-4.03%-2.13%-1.92%-1.23%1 Month Performance-5.85%-3.10%11.47%3.36%1 Year Performance-16.63%11.54%30.52%16.60% Regeneron Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REGNRegeneron Pharmaceuticals4.6587 of 5 stars$701.85-0.9%$1,052.90+50.0%-16.6%$77.13B$13.85B17.3713,450Analyst ForecastHigh Trading VolumeAMGNAmgen4.4715 of 5 stars$269.39-0.5%$319.68+18.7%-4.3%$144.81B$32.53B34.8626,700Analyst DowngradeGap UpVRTXVertex Pharmaceuticals4.7526 of 5 stars$466.88+0.7%$505.73+8.3%-0.7%$120.24B$9.87B-233.035,400Analyst ForecastAnalyst RevisionNews CoverageGILDGilead Sciences4.4929 of 5 stars$92.73+0.9%$96.43+4.0%+17.8%$115.57B$27.12B1,020.6718,000Insider TradePositive NewsALNYAlnylam Pharmaceuticals4.4132 of 5 stars$246.53+0.4%$298.09+20.9%+37.1%$31.80B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6302 of 5 stars$151.25+0.8%$245.32+62.2%-41.0%$22.04B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7129 of 5 stars$370.95+2.5%$370.860.0%+59.5%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8286 of 5 stars$134.00+5.8%$165.00+23.1%+12.6%$13.57B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7054 of 5 stars$70.38+2.7%$76.13+8.2%+13.3%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9845 of 5 stars$66.07+0.1%$94.20+42.6%-29.1%$12.59B$2.75B39.533,401Positive NewsEXASExact Sciences4.4914 of 5 stars$60.48-1.3%$72.94+20.6%-11.7%$11.19B$2.50B-52.356,600 Related Companies and Tools Related Companies Amgen Alternatives Vertex Pharmaceuticals Alternatives Gilead Sciences Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGN Stock Alerts